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Sodium channel myotonias are inherited muscle diseases
linked to mutations in the voltage-gated sodium (Nav1.4)
channel [1]. Today, mexiletine is empirically considered as a
first choice drug in non-dystrophic myotonias. Mexiletine
likely acts by reducing muscle cell excitability through use-
dependent Nav1.4 channel block. Nevertheless, not all
patients benefit from mexiletine because of side effects
(gastrointestinal discomfort, dizziness) or lack of efficacy.
Here we report the case of a mother and her son, both
carrying the G1306E sodium channel mutation associated
with a severe phenotype of myotonia permanens and little
improvement with mexiletine. Since the G1306E mutant
was more sensitive to flecainide than mexiletine in vitro
[2], we decided to shift treatment to flecainide.
The proband came to our observation when she was 20
years old, complaining since early childhood of severe and
painful generalized muscle stiffness, exacerbated after exer-
cise, in wet weather and during febrile episodes. Generalized
muscle hypertrophy was present. The lid-lag phenomenon
lasted for several seconds, while relaxation time of the grip
was lengthened to 30–40 s. Long exercise and cooling tests
did not induce weakness. Electromyography showed normal
nerve conduction but continuous myotonic running at rest.
Serum creatine kinase was elevated to 400–900 IU/L. A
biopsy of the left biceps muscle showed abnormal central
nuclei and fiber size. The G1306E mutation was found in
the SCN4A gene [3]. Previous electrophysiological studies
described the alteration of mutant sodium channel gating and
demonstrated its responsibility for the phenotype [3, 4]. Dur-
ing her life, the patient was given empiric trials of carbama-
zepine (3×200 mg/day), hydroquinidine (3×200 mg/day),
tocainide (3×400 mg/day), and mexiletine (4×200 mg/day)
with limited benefit.
During pregnancy (age 36 and 39 years), the proband
experienced a striking worsening of myotonia. One son is
affected, carrying the same G1306E mutation. He shows a
very severe phenotype, including facial and ocular muscle
myotonia since his birth, generalized painful muscle myo-
tonia, and muscle hypertrophy. His general motor and men-
tal development is normal. Since early childhood he has
taken mexiletine with very poor benefit. Examination at
age 5 years revealed forced internal rotation of the gleno-
humeral joint and elevation of the shoulders, probably due
to shoulder muscle stiffness and hypertrophy. Prolonged lid-
lag phenomenon was found associated with severe orbicular
myotonia, extraocular muscles and tongue myotonia.
On the basis of in vitro experiments [2], we decided to
initiate treatment with flecainide. In the proband (age 43
years, body weight 65 kg), mexiletine (4×200 mg/day) was
suspended in the afternoon and flecainide (100 mg/day)
assumed next morning. Ambulatory cardiac function was
evaluated. After 2 days of malaise, the patient started to
improve. Four days later, flecainide dose was increased to
100 mg twice a day. The patient noticed an enhanced capa-
bility to move spontaneously after rest and a dramatic im-
provement of her periorbital and extraocular myotonia.
One month later, the proband child (age 7 years, body
weight 25 kg) was changed from mexiletine to 35 mg
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flecainide twice a day. After 10 days, muscle stiffness de-
creased so that the internal rotation of the gleno-humeral
joint and elevation of the shoulders were significantly re-
duced. The mother reported that he became able to have a
meal and dress himself without any help. At last follow-up
the child was taking 60 mg flecainide twice a day.
A functional chair test [5] showed a remarkable improve-
ment after flecainide introduction and a further improve-
ment 9 months later (Fig. 1). The quality of life of the
proband was evaluated with the 36-Item Short-Form Health
Survey [6]. The physical component scale increased from 29
during mexiletine therapy to 38 after flecainide introduction.
Improvement included physical functioning, role limitations
due to physical problems, body pain, and general health
perceptions. After almost 2 years of treatment no side effects
have been reported.
There are only a few reports on myotonia permanens
associated with G1306E mutation, including a familial case
with autosomal dominant inheritance [7]. In this study, the
proband did not have any symptom relief with mexiletine,
oxcarbazepine, or thiazide diuretics. Although flecainide has
been shown to be an effective hNav1.4 channel blocker in
vitro [2, 8, 9], its clinical use as an antimyotonic agent is rarely
reported [10]. The improvement of myotonia by flecainide
obtained here suggests that there may be a relationship
between the G1306E mutation and the response to flecainide
therapy. Indeed we previously demonstrated that flecainide
was more efficient than mexiletine in blocking functionally
expressed G1306E channels, probably due to the positive shift
of channel availability voltage-dependence by the mutation
[2]. On the same basis, we may hypothesize that at least 15 out
of 33 identified SCN4A mutations, which are known to in-
duce a positive shift of voltage-dependence, may be more
sensitive to flecainide than mexiletine, and patients carrying
these mutations might have more benefit from flecainide.
Such hypothesis merits further investigation.
The present study provides a paradigm of a bench-to-
bedside pharmacogenetics strategy and indicates the rele-
vance of pursuing the pharmacological characterization of
sodium channel mutants in vitro in order to define a drug-
genotype relationship. A clinical trial would be then war-
ranted to develop a pharmacogenetic strategy to better ad-
dress treatment in individual myotonic patients. Such an
approach may be also of great interest in other familial
diseases, including cardiac arrhythmias, epilepsies, and neu-
ropathic pain, all characterized by mutations in sodium
channel genes and by possible treatment with sodium chan-
nel blockers.
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Fig. 1 Chair test. The functional chair test was performed at the same
time of day, in a comfortable room with an ambient temperature of 25 °
C. Both patients were asked to rise from a chair after a 5 min rest and
perform three turns around the chair as quickly as they could (T1). The
performance was repeated 5 min later (T2) and once again without any
rest (T3), in order to evaluate the warm-up phenomenon or paradoxical
worsening. The time spent to perform the exercise was measured with a
stopwatch. The test was performed when the patient was taking mex-
iletine, then 12 (test #1) and 21 (test #2) months after the introduction
of flecainide. The test showed a remarkable improvement in both
mother and son with flecainide treatment
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